ROSIGLITAZONE EFFCT ON ADIPCYTE-DERIVD CYTOKINES IN NONDIABTC PTS W/METABLC SYND

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定“胰岛素增敏剂”罗格列酮是否会有利地改变代谢综合征患者的脂肪细胞蛋白质。代谢综合征是一系列健康风险的集合，这些风险增加了一个人未来患2型糖尿病和心血管疾病的机会。由于代谢综合征在美国正以惊人的速度增加，因此确定替代方法来改变这一人群的疾病进展是至关重要的。罗格列酮可能有助于改变脂肪细胞制造的蛋白质的数量。这可能会提高身体利用胰岛素的能力，并影响代谢综合征的某些部分。目前，罗格列酮等药物的使用不是患有代谢综合征的人的标准护理。我们的研究是观察罗格列酮是否对患有代谢综合征的人有益的早期步骤。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine if rosiglitazone, an 'insulin sensitizer', will favorably alter fat cell proteins in people with the metabolic syndrome. The metabolic syndrome is a collection of health risks that increase a person's chance for the future development of type 2 diabetes and cardiovascular disease. Because the metabolic syndrome is increasing at alarming rates in the United States, identification of alternative ways to alter disease progression in this population is essential. Rosiglitazone may be helpful in altering the amount of proteins made by the fat cells. This may improve the body's ability to use insulin and impact some of the parts of the metabolic syndrome. Currently, use of medications, like rosiglitazone, is not standard of care in people who have the metabolic syndrome. Our study is an early step to see if rosiglitazone will be beneficial in people who have the metabolic syndrome.